Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
- PMID: 15194558
- DOI: 10.1152/ajpgi.00079.2004
Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation
Abstract
Patients with ulcerative colitis and Crohn's disease are at increased risk for developing colorectal cancer. To date, no known genetic basis has been identified to explain colorectal cancer predisposition in these inflammatory bowel diseases. Instead, it is assumed that chronic inflammation is what causes cancer. This is supported by the fact that colon cancer risk increases with longer duration of colitis, greater anatomic extent of colitis, the concomitant presence of other inflammatory manifestations such as primary sclerosing cholangitis, and the fact that certain drugs used to treat inflammation, such as 5-aminosalicylates and steroids, may prevent the development of colorectal cancer. The major carcinogenic pathways that lead to sporadic colorectal cancer, namely chromosomal instability, microsatellite instability, and hypermethylation, also occur in colitis-associated colorectal cancers. Unlike normal colonic mucosa, however, inflamed colonic mucosa demonstrates abnormalities in these molecular pathways even before any histological evidence of dysplasia or cancer. Whereas the reasons for this are unknown, oxidative stress likely plays a role. Reactive oxygen and nitrogen species produced by inflammatory cells can interact with key genes involved in carcinogenic pathways such as p53, DNA mismatch repair genes, and even DNA base excision-repair genes. Other factors such as NF-kappaB and cyclooxygenases may also contribute. Administering agents that cause colitis in healthy rodents or genetically engineered cancer-prone mice accelerates the development of colorectal cancer. Mice genetically prone to inflammatory bowel disease also develop colorectal cancer especially in the presence of bacterial colonization. These observations offer compelling support for the role of inflammation in colon carcinogenesis.
Similar articles
-
Intestinal inflammation and cancer.Gastroenterology. 2011 May;140(6):1807-16. doi: 10.1053/j.gastro.2011.01.057. Gastroenterology. 2011. PMID: 21530747 Review.
-
Chronic inflammatory bowel disease and cancer.Hepatogastroenterology. 2000 Jan-Feb;47(31):57-70. Hepatogastroenterology. 2000. PMID: 10690586 Review.
-
Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.Anticancer Res. 2009 Jul;29(7):2727-37. Anticancer Res. 2009. PMID: 19596953 Review.
-
Cancer surveillance in inflammatory bowel disease: new molecular approaches.Curr Opin Gastroenterol. 2006 Jul;22(4):382-90. doi: 10.1097/01.mog.0000231812.95525.a7. Curr Opin Gastroenterol. 2006. PMID: 16760754 Review.
-
Inflammatory bowel disease: a model of chronic inflammation-induced cancer.Methods Mol Biol. 2009;511:193-233. doi: 10.1007/978-1-59745-447-6_9. Methods Mol Biol. 2009. PMID: 19347299
Cited by
-
Colon-Targeted Sustained-Release Combinatorial 5-Fluorouracil and Quercetin poly(lactic-co-glycolic) Acid (PLGA) Nanoparticles Show Enhanced Apoptosis and Minimal Tumor Drug Resistance for Their Potential Use in Colon Cancer.ACS Pharmacol Transl Sci. 2024 Aug 20;7(9):2612-2620. doi: 10.1021/acsptsci.4c00462. eCollection 2024 Sep 13. ACS Pharmacol Transl Sci. 2024. PMID: 39296268
-
Inflammatory Bowel Disease and Colorectal Cancer.Cancers (Basel). 2024 Aug 23;16(17):2943. doi: 10.3390/cancers16172943. Cancers (Basel). 2024. PMID: 39272800 Free PMC article. Review.
-
The Role of Estrogen across Multiple Disease Mechanisms.Curr Issues Mol Biol. 2024 Jul 29;46(8):8170-8196. doi: 10.3390/cimb46080483. Curr Issues Mol Biol. 2024. PMID: 39194700 Free PMC article. Review.
-
Intestinal organ chips for disease modelling and personalized medicine.Nat Rev Gastroenterol Hepatol. 2024 Aug 27. doi: 10.1038/s41575-024-00968-3. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39192055 Review.
-
Targeting NETosis: nature's alarm system in cancer progression.Cancer Drug Resist. 2024 Jul 19;7:28. doi: 10.20517/cdr.2024.24. eCollection 2024. Cancer Drug Resist. 2024. PMID: 39143953 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous